Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.

This animal study found that berberine may alleviate benign prostatic hyperplasia by reducing inflammation and oxidative stress through inhibition of the NF-κB signaling pathway.

In this study on testosterone-induced benign prostatic hyperplasia in rats, hydroxychloroquine significantly reduced prostate-related markers and enhanced therapeutic effects when combined with finasteride, suggesting potential as a new treatment approach.

This study found that ureteroileal anastomosis with direct intraluminal visualization had a 4.2% stricture rate, which compares favorably to other techniques with rates between 3.5% and 11.1%.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This study suggests that a larger prostate is associated with a higher prevalence of androgenetic alopecia, although the prostate size did not correlate with alopecia severity.

In this study, corn silk extract treatment improved symptoms of testosterone-induced BPH by reducing specific mRNA expression and decreasing levels of 5α-R2, DHT, and PSA.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.

This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.

In this study, researchers observed that Cuscuta reflexa extract mitigated inflammation and oxidative stress in testosterone-induced benign prostatic hypertrophy in Wistar rats, suggesting its potential as an adjunctive therapy for BPH.

This study found that ethanol extract of Syzygium aromaticum (clove) leaves significantly improved lipid profiles and increased body weight in testosterone-induced benign prostatic hyperplasia rats, suggesting potential anti-hyperlipidemic effects and modulation of body weight through metabolic activity.

This study found significant species differences in the enzyme activity and inhibitor affinities of prostatic 5α-reductases from rats, dogs, and humans, with variable potencies for different 3-oxo-4-azasteroid inhibitors across species.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This study observed that in hormone-starved prostate cancer cells, the androgen 5alpha-dihydrotestosterone rapidly induces matriptase activation and shedding, which involves androgen receptor signaling and requires both transcription and protein synthesis.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This animal study found that Cinnamomi cortex water extract reduced prostate weight and improved histological changes in a benign prostatic hyperplasia model, suggesting potential as a treatment.

This review discusses the hormonal influences on prostate carcinogenesis and notes ongoing trials investigating whether finasteride could reduce prostate cancer incidence by inhibiting dihydrotestosterone synthesis, but it reports no new results.

This study found that Ganoderma lucidum extracts reduced prostate enlargement and improved symptoms in testosterone-treated rats, suggesting potential benefits for managing benign prostatic hyperplasia.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This study found that Monascus cursory extraction reduced baldness, prostate hyperplasia, and tumor incidence in animal models of androgen-related diseases, suggesting it may be a promising new therapeutic candidate.

This article discusses the hypothesis that mechanisms driving androgenic alopecia may reduce the risk and proliferation of prostate cancer by increasing prostaglandin D2 levels but presents no new clinical findings.

This study found that the petroleum ether extract of Citrullus colocynthis fruit and an isolated steroidal compound may reduce prostatic hyperplasia in rats induced by testosterone, suggesting potential use in managing androgen-dependent conditions.

This study found that certain steroidal compounds, especially 10a–10c, demonstrated strong antiandrogenic activity by binding to the androgen receptor and reducing prostate weight in a hamster model.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

This study found that high-dose pterostilbene potentially reduced prostate hyperplasia and had strong antioxidant effects in male rats with benign prostatic hyperplasia, suggesting it might be more effective than vitamin C and resveratrol in similar contexts.

This study identified 193 plasma proteins associated with prostate cancer risk, validating 20 high-risk proteins including KLK3, and pinpointed potential drug targets like HSPB1, RRM2B, and PSCA through genetic analysis, offering new insights for biomarkers and treatments.